Research programme: rare diseases therapeutics - Neuropore Therapeutics
Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Neuropore Therapies
- Class Small molecules
- Mechanism of Action Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Unspecified in USA
- 08 Sep 2020 Early research in Unspecified in USA (unspecified route) before September 2020 (Neuropore Therapies pipeline, September 2020)